2018-19 Section 7-Neoplastic and Inflammatory Diseases of the Head and Neck eBook

|

CHERAGHLOU ET AL .

management of high-risk salivary gland carcinomas. Head Neck. 2016;38(11):1628-1633. [27] Tanvetyanon T, Fisher K, Caudell J, Otto K, Padhya T, Trotti A. Adjuvant chemoradiotherapy versus with radiotherapy alone for locally advanced salivary gland carcinoma among older patients. Head Neck. 2016;38(6):863-870. [28] Amini A, Waxweiler TV, Brower JV, et al. Association of adju- vant chemoradiotherapy vs radiotherapy alone with survival in patients with resected major salivary gland carcinoma: data from the National Cancer Data Base. JAMA Otolaryngol Head Neck Surg. 2016;142(11):1100-1110. [29] Hsieh CE, Lin CY, Lee LY, et al. Adding concurrent chemother- apy to postoperative radiotherapy improves locoregional control but not overall survival in patients with salivary gland adenoid cystic carcinoma-a propensity score matched study. Radiat Oncol. 2016;11:47. [30] Bilimoria KY, Stewart AK, Winchester DP, Ko CY. The National Cancer Data Base: a powerful initiative to improve can- cer care in the United States. Ann Surg Oncol. 2008;15(3):683- 690. [31] Christakis NA, Iwashyna TJ. The health impact of health care on families: a matched cohort study of hospice use by decedents and mortality outcomes in surviving, widowed spouses. Soc Sci Med. 2003;57(3):465-475. [32] Iwashyna TJ, Lamont EB. Effectiveness of adjuvant fluorouracil in clinical practice: a population-based cohort study of elderly patients with stage III colon cancer. J Clin Oncol. 2002;20(19): 3992-3998. [33] Park HS, Gross CP, Makarov DV, Yu JB. Immortal time bias: a frequently unrecognized threat to validity in the evaluation of postoperative radiotherapy. Int J Radiat Oncol Biol Phys. 2012; 83(5):1365-1373. [34] Javitt JC, McBean AM, Nicholson GA, Babish JD, Warren JL, Krakauer H. Undertreatment of glaucoma among black Ameri- cans. N Engl J Med. 1991;325(20):1418-1422. [35] Sheifer SE, Escarce JJ, Schulman KA. Race and sex differences in the management of coronary artery disease. Am Heart J. 2000;139(5):848-857. [36] Epstein AM, Ayanian JZ, Keogh JH, et al. Racial disparities in access to renal transplantation – clinically appropriate or due to underuse or overuse? N Engl J Med. 2000;343(21):1537-1544. [37] McBean AM, Gornick M. Differences by race in the rates of procedures performed in hospitals for Medicare beneficiaries. Health Care Financ Rev. 1994;15(4):77-90. [38] Ayanian JZ, Zaslavsky AM, Fuchs CS, et al. Use of adjuvant chemotherapy and radiation therapy for colorectal cancer in a population-based cohort. J Clin Oncol. 2003;21(7):1293-1300. [39] Schrag D, Cramer LD, Bach PB, Begg CB. Age and adjuvant chemotherapy use after surgery for stage III colon cancer. J Natl Cancer Inst. 2001;93(11):850-857. [40] Bach PB, Cramer LD, Warren JL, Begg CB. Racial differences in the treatment of early-stage lung cancer. N Engl J Med. 1999; 341(16):1198-1205. [41] Earle CC, Neumann PJ, Gelber RD, Weinstein MC, Weeks JC. Impact of referral patterns on the use of chemotherapy for lung cancer. J Clin Oncol. 2002;20(7):1786-1792.

[10] Garden AS, Weber RS, Ang KK, Morrison WH, Matre J, Peters LJ. Postoperative radiation therapy for malignant tumors of minor salivary glands. Outcome and patterns of failure. Cancer. 1994;73(10):2563-2569. [11] Theriault C, Fitzpatrick PJ. Malignant parotid tumors. Prognostic factors and optimum treatment. Am J Clin Oncol. 1986;9(6):510- 516. [12] Armstrong JG, Harrison LB, Spiro RH, Fass DE, Strong EW, Fuks ZY. Malignant tumors of major salivary gland origin: a matched-pair analysis of the role of combined surgery and post- operative radiotherapy. Arch Otolaryngol Head Neck Surg. 1990;116(3):290-293. [13] Fu KK, Leibel SA, Levine ML, Friedlander LM, Boles R, Phil- lips TL. Carcinoma of the major and minor salivary glands: analysis of treatment results and sites and causes of failures. Cancer. 1977;40(6):2882-2890. [14] Black KM, Fitzpatrick PJ, Palmer JA. Adenoid cystic carcinoma of the salivary glands. Can J Surg. 1980;23(1):32-35. [15] Guillamondegui OM, Byers RM, Luna MA, Chiminazzo H Jr, Jesse RH, Fletcher GH. Aggressive surgery in treatment for parotid cancer: the role of adjunctive postoperative radiotherapy. Am J Roentgenol Ther Nucl Med. 1975;123(1):49-54. [16] Mendenhall WM, Morris CG, Amdur RJ, Werning JW, Villaret DB. Radiotherapy alone or combined with surgery for salivary gland carcinoma. Cancer. 2005;103(12):2544-2550. [17] Vissink A, Burlage FR, Spijkervet FK, Jansma J, Coppes RP. Prevention and treatment of the consequences of head and neck radiotherapy. Crit Rev Oral Biol Med. 2003;14(3):213-225. [18] Vissink A, Jansma J, Spijkervet FK, Burlage FR, Coppes RP. Oral sequelae of head and neck radiotherapy. Crit Rev Oral Biol Med. 2003;14(3):199-212. [19] Jansma J, Vissink A, Spijkervet FK, et al. Protocol for the pre- vention and treatment of oral sequelae resulting from head and neck radiation therapy. Cancer. 1992;70(8):2171-2180. [20] Shen C, Xu T, Huang C, Hu C, He S. Treatment outcomes and prognostic features in adenoid cystic carcinoma originated from the head and neck. Oral Oncol. 2012;48(5):445-449. [21] Silverman DA, Carlson TP, Khuntia D, Bergstrom RT, Saxton J, Esclamado RM. Role for postoperative radiation therapy in adenoid cystic carcinoma of the head and neck. Laryngoscope. 2004;114(7):1194-1199. [22] Elkon D, Colman M, Hendrickson FR. Radiation therapy in the treatment of malignant salivary gland tumors. Cancer. 1978;41 (2):502-506. [23] Mahmood U, Koshy M, Goloubeva O, Suntharalingam M. Adju- vant radiation therapy for high-grade and/or locally advanced major salivary gland tumors. Arch Otolaryngol Head Neck Surg. 2011;137(10):1025-1030. [24] Tanvetyanon T, Qin D, Padhya T, et al. Outcomes of postopera- tive concurrent chemoradiotherapy for locally advanced major salivary gland carcinoma. Arch Otolaryngol Head Neck Surg. 2009;135(7):687-692. [25] Hocwald E, Korkmaz H, Yoo GH, et al. Prognostic factors in major salivary gland cancer. Laryngoscope. 2001;111(8):1434-1439. [26] Mifsud MJ, Tanvetyanon T, McCaffrey JC, et al. Adjuvant radiotherapy versus concurrent chemoradiotherapy for the

56